BioCentury
ARTICLE | Company News

EC approves linaclotide

November 29, 2012 1:57 AM UTC

The European Commission approved Constella linaclotide from Almirall S.A. (Madrid:ALM) and partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) to treat moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. Almirall, which has exclusive European rights to linaclotide from Ironwood, plans to launch Constella in Europe next half. Ironwood said pricing for the guanylate cyclase C ( GCC; GUCY2C) agonist is not yet available. ...